Literature DB >> 27287929

Control and Eradication Strategies of Hepatitis B Virus.

Chiaho Shih1, Shu-Fan Chou2, Ching-Chun Yang3, Jyun-Yuan Huang2, Gansukh Choijilsuren3, Ren-Shiang Jhou2.   

Abstract

Hepatitis B virus (HBV) is a major human pathogen, and chronic hepatitis can lead to cirrhosis and malignant hepatocellular carcinoma. While HBV vaccine and treatment are available, it has remained a challenge to completely eradicate the virus from patients. Current therapy using either interferon or polymerase inhibitors cannot cure HBV with a high efficacy. Lifelong therapy is needed to suppress HBV in patients who achieve no seroconversion. Here, we review recent exciting advances of new strategies, including the inhibition of viral entry, the destruction or silencing of HBV covalently closed circular DNA (cccDNA), and breaking immune tolerance. Combinations of different therapeutic strategies could improve the cure rate of viral persistence in chronic hepatitis B.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  chronic infection; combination therapy; covalently closed circular DNA (cccDNA); hepatitis B virus; immune tolerance; viral entry

Mesh:

Substances:

Year:  2016        PMID: 27287929     DOI: 10.1016/j.tim.2016.05.006

Source DB:  PubMed          Journal:  Trends Microbiol        ISSN: 0966-842X            Impact factor:   17.079


  22 in total

Review 1.  Mechanisms of Hepatitis B Virus Persistence.

Authors:  Kuen-Nan Tsai; Cheng-Fu Kuo; Jing-Hsiung James Ou
Journal:  Trends Microbiol       Date:  2017-08-16       Impact factor: 17.079

2.  Characterization of small genomic regions of the hepatitis B virus should be performed with more caution.

Authors:  Lei Jia; Fengyu Hu; Hanping Li; Lin Li; Xiaoping Tang; Yongjian Liu; Haohui Deng; Jingwan Han; Jingyun Li; Weiping Cai
Journal:  Virol J       Date:  2018-12-10       Impact factor: 4.099

3.  Hepatitis B virus virion secretion is a CRM1-spike-mediated late event.

Authors:  Pei-Yi Su; Shin-Chwen Bruce Yen; Ching-Chun Yang; Chih-Hsu Chang; Wen-Chang Lin; Chiaho Shih
Journal:  J Biomed Sci       Date:  2022-06-21       Impact factor: 12.771

Review 4.  Prevention of HBV Reactivation in Hemato-Oncologic Setting during COVID-19.

Authors:  Caterina Sagnelli; Antonello Sica; Massimiliano Creta; Alessandra Borsetti; Massimo Ciccozzi; Evangelista Sagnelli
Journal:  Pathogens       Date:  2022-05-11

Review 5.  Future Therapy for Hepatitis B Virus: Role of Immunomodulators.

Authors:  Edward A Pham; Ryan B Perumpail; Benjamin J Fram; Jeffrey S Glenn; Aijaz Ahmed; Robert G Gish
Journal:  Curr Hepatol Rep       Date:  2016-11-10

6.  Heparin at physiological concentration can enhance PEG-free in vitro infection with human hepatitis B virus.

Authors:  Gansukh Choijilsuren; Ren-Shiang Jhou; Shu-Fan Chou; Ching-Jen Chang; Hwai-I Yang; Yang-Yuan Chen; Wan-Long Chuang; Ming-Lung Yu; Chiaho Shih
Journal:  Sci Rep       Date:  2017-10-31       Impact factor: 4.379

Review 7.  Drugs in Development for Hepatitis B.

Authors:  Altaf Dawood; Syed Abdul Basit; Mahendran Jayaraj; Robert G Gish
Journal:  Drugs       Date:  2017-08       Impact factor: 9.546

8.  MicroRNA miR-204 and miR-1236 inhibit hepatitis B virus replication via two different mechanisms.

Authors:  Jyun-Yuan Huang; Hung-Lin Chen; Chiaho Shih
Journal:  Sci Rep       Date:  2016-10-13       Impact factor: 4.379

9.  STAT3-Dependent Gene TRIM5γ Interacts With HBx Through a Zinc Binding Site on the BBox Domain.

Authors:  Hongxiao Song; Fengchao Xu; Xiaoli Pang; Qingfei Xiao; Qi Wei; Bingxin Lei; Xiaolu Li; Xixi Fan; Guangyun Tan
Journal:  Front Microbiol       Date:  2021-07-02       Impact factor: 5.640

10.  HBV maintains electrostatic homeostasis by modulating negative charges from phosphoserine and encapsidated nucleic acids.

Authors:  Pei-Yi Su; Ching-Jen Yang; Tien-Hua Chu; Chih-Hsu Chang; Chiayn Chiang; Fan-Mei Tang; Chih-Yin Lee; Chiaho Shih
Journal:  Sci Rep       Date:  2016-12-13       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.